Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.8386
-0.0124 (-1.46%)
At close: Mar 28, 2025, 4:00 PM
0.8451
+0.0065 (0.78%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Coherus BioSciences Revenue
In the year 2024, Coherus BioSciences had annual revenue of $266.96M with 3.78% growth. Coherus BioSciences had revenue of $54.14M in the quarter ending December 31, 2024, a decrease of -40.84%.
Revenue (ttm)
$266.96M
Revenue Growth
+3.78%
P/S Ratio
0.37
Revenue / Employee
$1,170,877
Employees
228
Market Cap
97.19M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.96M | 9.72M | 3.78% |
Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCHRS News
- 3 days ago - Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 18 days ago - Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 25 days ago - Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 - GlobeNewsWire
- 4 weeks ago - Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 3 months ago - Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - GlobeNewsWire
- 3 months ago - Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
- 4 months ago - Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Benzinga